Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats
Section snippets
Acknowledgements
We wish to thank C. Koelske, A. Loechner, R. Winter and M. Witt for their excellent technical assistance. This study was supported by grants of the Deutsche Forschungsgemeinschaft (Ku 830/3–1,3–3) and the European Community (QLK6–1999–02173).
References (18)
- et al.
Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA
Biochem. Behav. Pharmacol
(1980) - et al.
Activation of the subthalamic nucleus and pedunculopontine tegmentum: Does it affect dopamine levels in the substantia nigra, nucleus accumbens and striatum?
Neurodegeneration
(1995) - et al.
Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat
Exp. Neurol.
(1998) - et al.
Do N.M.D.A. receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice
Brain. Res.
(1992) - et al.
The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat
Neurosci. Lett.
(2000) - et al.
Stimulation of the subthalamic nucleus enhances the release of dopamine in the rat substantia nigra
Brain. Res.
(1986) - et al.
In vivo dialysis measurements of dopamine and DOPAC in rats trained to turn on a circular treadmill
Pharmacol. Biochem. Behav.
(1990) - et al.
Progressive degeneration of nigrostriatal neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunoytochemical study in the rat
Neuroscience
(1994) - et al.
Long-term electrical inhibition of deep brain targets in movement disorders
Mov. Disord. (Suppl.)
(1998)
Cited by (74)
Effects of subthalamic nucleus deep brain stimulation on neuronal spiking activity in the substantia nigra pars compacta in a rat model of Parkinson's disease
2020, Neuroscience LettersCitation Excerpt :The findings contrasted to expectations, since others had reported that STN-DBS increased excitatory post-synaptic potentials in the SNc in vitro [12], increased dopamine concentrations in the striatum [11], and increased STN spiking activity in vivo in naïve rats [2]. Others also reported that STN-DBS increased striatal dopamine in urethane-anesthetized [16] and awake, freely-moving hemiparkinsonian rats [15]. These changes were plausibly brought about via enhanced excitatory glutamatergic neurotransmitter signaling from STN to SNc neurons, and indirectly by activating cholinergic and/or glutamatergic pedunculopontine tegmental (PPT) neurons in the STN-PPT-SNc neurocircuitry during STN-DBS [13].
The pathophysiological mechanisms of motivational deficits in Parkinson's disease
2018, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :The other mechanism suggested is that apathy observed in STN-DBS patients may be caused by the degeneration of the DA mesolimbic pathway (Thobois et al., 2010). Animal models of PD using in vivo microdialysis have demonstrated that STN-DBS enhanced DA release and metabolism in striatum (Bruet et al., 2001; Lacombe et al., 2007; Meissner et al., 2002, 2003, 2001; Paul et al., 2000; Pazo et al., 2010) improving PD motor symptoms (Zhao et al., 2009). Considering that the STN-DBS is effective only against levodopa-sensitive motor symptoms and the possible reduction of DA-ergic therapy of up to 50% in parkinsonian subjects on chronic STN-DBS application, multiple authors postulated that variation in striatal DA-ergic activity may contribute to the clinical benefits of STN-DBS (Benabid et al., 1998; Krack et al., 2003; Limousin et al., 1995; Moro et al., 1999).